https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Large Real-World Study Validates Idecabtagene Vicleucel Outcomes Seen in KarMMa Trial

Large Real-World Study Validates Idecabtagene Vicleucel Outcomes Seen in KarMMa Trial

The data showed patients with relapsed or refractory multiple myeloma achieved a 73% overall response rate.

administrator

Related Articles